Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Zyn-NP** is a branded nicotine pouch product designed as an alternative to tobacco smoking. It delivers **nicotine** via the oral mucosa when placed between the upper lip and gum for a defined period, typically 30 minutes. The main ingredient is nicotine; the product is tobacco-free, using fillers, flavorings, and stabilizers to create the pouch. In clinical settings, Zyn-NP is used as a comparator for other nicotine pouches to evaluate pharmacokinetics—specifically absorption, maximum plasma concentration, and subjective effects such as craving and satisfaction. Zyn-NP delivers lower maximum plasma nicotine concentrations (Cmax) and total nicotine absorption over time (AUC) compared to similar products, yet demonstrates favorable subjective liking scores[1][2][3]. The developer and main manufacturer is Swedish Match, known for producing Zyn-branded nicotine devices. Zyn-NP's mechanism of action involves **nicotine acting as an agonist at nicotinic acetylcholine receptors**, providing stimulation of the central nervous system, reduction in cigarette craving, and mild euphoria. Primary indication is for **smoking cessation or harm reduction** among nicotine users.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zyn-NP.